242 related articles for article (PubMed ID: 19476859)
41. Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States.
Mohiuddin JJ; Deal AM; Carey LA; Lund JL; Baker BR; Zagar TM; Jones EL; Marks LB; Chen RC
J Am Coll Surg; 2016 Nov; 223(5):717-728.e4. PubMed ID: 27788894
[TBL] [Abstract][Full Text] [Related]
42. [Neoadjuvant endocrine therapy for locally advanced breast cancer].
Viola G; Sergi D; Conti F; Lopez M
Clin Ter; 2007; 158(5):441-52. PubMed ID: 18062352
[TBL] [Abstract][Full Text] [Related]
43. Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
Tan WW; Allred JB; Moreno-Aspitia A; Northfelt DW; Ingle JN; Goetz MP; Perez EA
Clin Breast Cancer; 2016 Apr; 16(2):82-6. PubMed ID: 26774555
[TBL] [Abstract][Full Text] [Related]
44. Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation.
Boughey JC; Wagner J; Garrett BJ; Harker L; Middleton LP; Babiera GV; Meric-Bernstam F; Lucci A; Hunt KK; Bedrosian I
Ann Surg Oncol; 2009 Jun; 16(6):1606-11. PubMed ID: 19280264
[TBL] [Abstract][Full Text] [Related]
45. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy.
Dixon JM; Renshaw L; Dixon J; Thomas J
Breast Cancer Res Treat; 2011 Dec; 130(3):871-7. PubMed ID: 21870129
[TBL] [Abstract][Full Text] [Related]
46. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
47. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
48. Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
Pedersini R; Amoroso V; Maffezzoni F; Gallo F; Turla A; Monteverdi S; Ardine M; Ravanelli M; Vassalli L; Rodella F; Formenti AM; Dalla Volta A; Simoncini EL; Giustina A; Maroldi R; Berruti A
JAMA Netw Open; 2019 Sep; 2(9):e1911080. PubMed ID: 31560383
[TBL] [Abstract][Full Text] [Related]
49. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
[TBL] [Abstract][Full Text] [Related]
50. Patients with invasive lobular breast cancer are less likely to undergo breast-conserving surgery: a population based study in the Netherlands.
Truin W; Roumen RM; Siesling S; van der Heiden-van der Loo M; Duijm LE; Tjan-Heijnen VC; Voogd AC
Ann Surg Oncol; 2015 May; 22(5):1471-8. PubMed ID: 25323475
[TBL] [Abstract][Full Text] [Related]
51. Opportunities to reduce reoperations and to improve inter-facility profiling after initial breast-conserving surgery for cancer. A report from the NCDB.
Landercasper J; Bennie B; Ahmad HF; Linebarger JH
Eur J Surg Oncol; 2019 Nov; 45(11):2026-2036. PubMed ID: 31383386
[TBL] [Abstract][Full Text] [Related]
52. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
Bhatnagar AS
Breast; 2006 Feb; 15 Suppl 1():S3-13. PubMed ID: 16500235
[TBL] [Abstract][Full Text] [Related]
53. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial.
Loibl S; von Minckwitz G; Raab G; Blohmer JU; Dan Costa S; Gerber B; Eidtmann H; Petrich S; Hilfrich J; Jackisch C; du Bois A; Kaufmann M
Ann Surg Oncol; 2006 Nov; 13(11):1434-42. PubMed ID: 16983592
[TBL] [Abstract][Full Text] [Related]
54. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
Straver ME; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Wesseling J; Russell NS; Oldenburg HS; Antonini N; Vrancken Peeters MT
Ann Surg Oncol; 2010 Sep; 17(9):2411-8. PubMed ID: 20373039
[TBL] [Abstract][Full Text] [Related]
55. Breast-Contour-Preserving Procedure as a Multidisciplinary Parameter of Esthetic Outcome in Breast Cancer Treatment in The Netherlands.
van Bommel A; Spronk P; Mureau M; Siesling S; Smorenburg C; Tollenaar R; Vrancken Peeters MJ; van Dalen T
Ann Surg Oncol; 2019 Jun; 26(6):1704-1711. PubMed ID: 30830541
[TBL] [Abstract][Full Text] [Related]
56. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
58. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
[TBL] [Abstract][Full Text] [Related]
59. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
60. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
